Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nancy Holekamp

Ophthalmology Chesterfield, MO Medical Doctor

NPI 1831197557 CMS profile 173773

1815 Clarkson Rd, Chesterfield, MO 63017

Open in the dashboard

General payments

$768,021

496 records reported · program years 2019–2025

Research payments

$62,939

Paid to them · 28 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,945,591 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Nancy Holekamp of Chesterfield, MO is reported in the CMS Open Payments database as having received $768,021 across 496 general payments and $62,939 in research payments paid to them. Separately, studies naming them as principal investigator received $1,945,591 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $300 1
2024 Research $15,907 16
2023 General $3,150 2
2023 Research $849 1
2022 General $201,501 146
2022 Research $2,397 4
2021 General $134,541 72
2021 Research $12,351 4
2020 General $159,312 90
2020 Research $31,435 3
2019 General $269,217 185

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Holekamp
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Nancy Holekamp were reported at $300. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Nancy Holekamp Ophthalmology median Middle half National median
2019 $269,217 $258 $104–$655 $163
2020 $159,312 $126 $45–$321 $114
2021 $134,541 $205 $76–$534 $132
2022 $201,501 $266 $100–$678 $149
2023 $3,150 $308 $117–$745 $160
2024 $0 $340 $127–$846 $164
2025 $300 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $183,236 88 payments
  2. Allergan Inc. $125,881 110 payments
  3. Genentech USA, Inc. $98,996 74 payments
  4. F. Hoffmann-La Roche AG $88,693 26 payments
  5. Genentech, Inc. $76,265 27 payments
  6. Novartis Pharmaceuticals Corporation $53,760 30 payments
  7. Apellis Pharmaceuticals, Inc. $31,281 17 payments
  8. Regeneron Pharmaceuticals, Inc. $23,907 15 payments
  9. Spark Therapeutics, Inc. $17,323 11 payments
  10. Roche Products Limited $14,852 6 payments
  11. Other $53,828 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $424,831 143 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $286,288 80 payments
  3. Travel and Lodging $40,196 63 payments
  4. Food and Beverage $10,087 204 payments
  5. Honoraria $4,700 3 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,000 1 payment
  7. Education $919 2 payments
Products named General payments · program years 2019–2025
  1. EYLEA $207,143 103 payments
  2. VABYSMO $77,956 39 payments
  3. OZURDEX $67,909 66 payments
  4. Lucentis $62,103 45 payments
  5. BEOVU $51,123 26 payments
  6. SUSVIMO $40,695 24 payments
  7. Non-Covered Product $31,048 11 payments
  8. LUXTURNA $17,323 11 payments
  9. XIPERE $12,645 15 payments
  10. YUTIQ $6,883 9 payments
  11. Other $5,821 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $57,754 26 payments
  2. Genentech, Inc. $5,185 2 payments

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record